Clearmind Medicine Inc. CMND

What this company does

Clearmind, a clinical stage pharmaceutical company, is engaged in phase I/IIa clinical trials of psychedelic medicines. It has two part-time employees and engages consultants and service providers, including outsourced research and development providers, with all of its employees located in Israel and Canada. Its research programs are focused on the uses of MEAI, a proprietary non-hallucinogenic compound, for the treatment of AUD, weight loss and metabolic disorders and as an alcohol substitute consumer product. MEAI is a synthetic molecule, and it is the active pharmaceutical ingredient of the drug candidate CMND-100. The company was granted approval by the Israeli Ministry of Health and by the FDA to initiate its first-in-human Phase I/IIa clinical trial with CMND-100 in patients suffering from AUD. The CM-CMND-001 clinical trial is designed as a multinational, multi-center, double blind, Phase I/IIa single- and multiple-dose tolerability, safety and pharmacokinetic study in healthy volunteers and AUD subjects.

Written from the business description in Clearmind Medicine Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 20 January 2026. Every sentence was checked against that document before publication.